MEDICLIN Reports Solid First Half of 2024

Offenburg, 31 July 2024: MEDICLIN Aktiengesellschaft (MEDICLIN) has reported consolidated sales of EUR 368.0 million for the first half of 2024, marking an increase of 0.9% from the same period in 2023. The group's EBIT rose slightly to EUR 11.9 million, up from EUR 11.3 million in the first half of the previous year. Capacity utilization also saw a year-on-year improvement, reaching 85.2%.

Dr Joachim Ramming, CEO, noted the company's preparedness amidst a dynamic environment, driven by upcoming hospital reforms and ongoing projects in ambulatory and digitalization. CFO Tino Fritz highlighted a robust adjusted sales growth of 6.8%, attributing the absence of protective shield benefits to the solid operating performance.

In the post-acute segment, sales increased by 4.9% to EUR 233.3 million. Despite a slight decrease in segment operating profit, the cost of materials and personnel expenses showed moderate growth. Conversely, the acute segment faced a 7.9% decline in sales but improved its segment operating loss to EUR -3.9 million.

Other activities, including the nursing care business, saw a 21.0% increase in sales, totaling EUR 14.4 million. However, the segment operating profit remained negative at EUR -1.6 million.

The Management Board anticipates a sales decline of 0.0% to 2.0% for the current fiscal year. The group operating result is expected to be between EUR 33.0 million and EUR 39.0 million.